RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled

RenovoRx, Inc.

2025-Q1 EPS reported -$0.08 revenue$197,000

First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.
TIGeR-PaC trial: 90 of 114 patients randomized; 50 of 86 events; 2nd interim analysis at 52nd event expected Q2 2025.
Cash $7.2M at 2024 year-end; $10.9M net raised in Feb 2025 public offering.
Net loss $8.8M in 2024 vs $10.2M in 2023; R&D $6.0M, SG&A $5.0M.
Shares outstanding 36.5M as of March 25, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.